Acorda Therapeutics (ACOR) Tops Q3 EPS by 13c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. USO
5. GNK
6. PLUR
7. MU
8. ARGX
9. AZN
10. SPCX

Go back to Acorda Therapeutics (ACOR) Tops Q3 EPS by 13c

Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

November 9, 2021 4:01 PM EST

INBRIJA® (levodopa inhalation powder) Q3 2021 net revenue of $7.8 million; 34% increase over Q3 2020 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg Q3 2021 net revenue of $20.0 million Agreement with ESTEVE to commercialize INBRIJA in Germany; 5 million upfront payment; launch expected mid-2022 Michael Gesser, M.B.A., joins company as Chief Financial Officer Neil Belloff, J.D., joins company as General Counsel Burkhard Blank, M.D., Chief Medical Officer, transitioning to consulting role at year end

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq:... More